1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSupports studies on normal cardiac function and pathogenesis to improve diagnosis, treatment, and prevention of heart failure and arrhythmias, including myocardial protection and resuscitation science.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Academic institutions, nonprofit organizations, and other entities conducting biomedical research. Confirm the full requirements in the official notice before applying.
Heart Failure & Arrhythmias Research is funded by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). This funding opportunity invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. The purpose is to engage small businesses in developing technologies and products that engage, empower, and motivate individuals and communities, including providers and healthcare institutions, to improve minority health and eliminate health disparities. This can include mobile health and telehealth technologies, and promoting big data science or enhancing data scientist training to address health inequities.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). Provides funding to small businesses to bridge the gap between Phase II and commercialization for heart, lung, blood, and sleep disorder technologies.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article